Pyrazine Amide Compounds for Lung Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for treating respiratory and allergic diseases related to the blockade of epithelial sodium channels have limitations in duration of activity and permeability, particularly for topical lung treatments.
Innovation Solution
Development of new compounds of formula 1, which are designed to have longer-lasting activity and reduced permeability, suitable for topical lung treatment, and their use in pharmaceutical compositions for treating respiratory and allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current compounds are used for topical lung treatment, then ENaC blockade activity is achieved, but treatment duration is insufficient and permeability is too high
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of the ENaC inhibitor molecules. Specifically, it changes the R1 substituent groups on the pyrazine core structure (including variations in chain length, branching, and functional groups) to optimize the balance between treatment duration and permeability. This chemical structure-parameter optimization enables sustained topical lung treatment while controlling permeability characteristics.
2Reliability
If compound activity is increased for effective disease treatment, then therapeutic efficacy improves, but permeability control becomes more difficult
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions (R1 substituents) on the molecular structure. Different local modifications (such as varying alkyl chains, aromatic groups, or heterocyclic substituents at specific positions) create localized changes in molecular properties that enhance therapeutic efficacy while independently controlling permeability characteristics.
Solution Approach 2:
The patent employs composite molecular structures combining a core pyrazine-2,3-dicarboxamide scaffold with diverse R1 substituent variations. This composite approach integrates multiple functional characteristics within single molecules, achieving both potent ENaC blockade activity and optimized permeability profiles for topical lung delivery.
Data Source
AI summary
The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.